Australia: Healthcare and competition update - ACCC to focus on pathology and oncology-radiology sectors in new merger regime

In brief

Proposed changes to Australia's merger control regime were introduced to Parliament last month following extensive public consultation. For further information on these reforms, please see our alerts here, here, and here.

As a key element of the reforms, the new legislation will enable the ACCC to request that the Treasurer designate certain sectors of the economy where all mergers, acquisitions or other transactions would require approval from the ACCC, regardless of transaction size.

Comments made by the ACCC and the Treasury over the course of the reform consultation process indicate that the ACCC will use its increased powers under the new regime to examine transactions in the pathology and oncology-radiology sectors.

As early as March 2023, the ACCC identified the pathology sector as an area of concern due to apparent market concentration. This concern was echoed in the ACCC’s submissions to the Treasury’s Competition Taskforce in January this year. Similarly, Treasurer Jim Chalmers confirmed in his Second Reading Speech of the Bill that the Government would consider designation requirements for the oncology-radiology sector.


Contents

Designation under the new regime is anticipated to lead to a considerable rise in both time and costs for parties involved in transactions within these sectors.

In more detail

More recently, in an interview with the Australian Financial Review (AFR), ACCC Chair Gina Cass-Gottlieb expressly stated that once the new laws were passed through Parliament, the ACCC would request the Treasurer to designate the pathology and oncology-radiology sectors due to the ACCC's concerns over concentration in these markets.

With respect to the oncology-radiology sector, the ACCC has previously expressed concern about the market concentration for cancer radiation clinics specifically, where two companies operate most private radiation clinics in Australia. Additionally, in its outline to the Treasury in March 2023, the ACCC identified the pathology services sector as being highly concentrated, with a small number of providers retaining significant market shares over time. The ACCC’s views in this regard are evidenced by its use of existing powers to prevent transactions in markets for the supply of community pathology services. In December 2023, it blocked a merger between the second- and third-largest pathology providers in Australia on the grounds that it would lead to a substantial lessening of competition in that market.

Finally, the ACCC has expressed ongoing concern about serial acquisitions and roll-ups in the cancer radiology and pathology sectors by private equity firms. The ACCC initially identified serial acquisitions as an issue affecting the pathology sector in its submissions to the Competition Taskforce in January 2024. In this vein, Ms Cass-Gottlieb’s comments indicate that the ACCC expects the designation function proposed by the new merger laws to enhance the visibility of these types of transactions and ensure they are subject to review by the ACCC. 

Businesses should anticipate that, unlike under the current voluntary notification regime, transactions within these sectors following the implementation of the reforms will be reviewed by the ACCC. It is also expected that the time and costs for businesses seeking clearance from the ACCC for these transactions will increase. 


Copyright © 2024 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.